
Cardiff Oncology (CRDF) Stock Forecast & Price Target
Cardiff Oncology (CRDF) Analyst Ratings
Bulls say
Cardiff Oncology is viewed positively because it has resolved all outstanding litigation with Nerviano, strengthening control over onvansertib’s global rights and reducing strategic uncertainty around its lead PLK1 inhibitor. The amended agreement also preserves exclusivity, adds revised economics tied to future sales and development milestones, and aligns governance as the company advances its Phase 3 program. Fundamentally, the investment case is reinforced by CRDF-004 data showing a 72.2% ORR versus 42.1% in control and median PFS not reached versus about 11 months, alongside a manageable safety profile in first-line RAS-mutated mCRC.
Bears say
Cardiff Oncology is facing a material legal and operational overhang after Nerviano Medical Sciences notified it on May 27, 2026 of termination of the onvansertib license, alleging material breach tied to inventorship correction and insufficient commercially reasonable development efforts. This dispute threatens control over the company’s main clinical asset, including regulatory communications, development data, and ongoing trial oversight, which could disrupt the Phase 2 program in first-line RAS-mutated metastatic colorectal cancer and weaken confidence in the broader PLK1 strategy. With unresolved litigation in Case No. 3:26-cv-3131-RBM-JLB and repeated termination threats from Nerviano since April 20, 2026, the stock faces elevated execution and partnering risk until legal clarity emerges.
This aggregate rating is based on analysts' research of Cardiff Oncology and is not a guaranteed prediction by Public.com or investment advice.
Cardiff Oncology (CRDF) Analyst Forecast & Price Prediction
Start investing in Cardiff Oncology (CRDF)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Cardiff Oncology (CRDF) Forecast
Cardiff Oncology (CRDF) Analyst Forecast & Price Prediction
Start investing in Cardiff Oncology (CRDF)
Order type
Buy in
Order amount
Est. shares
0 shares